Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With GD2-expressing Brain Tumors (GAIL-B)

NCT04099797 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT04099797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04099797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With GD2-expressing Brain Tumors (GAIL-B)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
February 3, 2020
Completion date
February 28, 2041
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma, embryonal tumor, ependymal tumor, high grade glioma